What is the clinical evidence from this study?

Study design: Cohort. Population: Severe aortic valve stenosis (n=79). Intervention: Transcatheter aortic valve implantation (TAVI) vs. Baseline (pre-TAVI). Primary outcome: Change in plasma levels of novel cardiovascular biomarkers (GDF-15, H-FABP, fetuin-A, galectin 3, sST2, and suPAR) (p=<0.001).

synapse

⌘+K

July 25, 2018

Multi-biomarker analysis in patients after transcatheter aortic valve implantation (TAVI)

Q: What are the key findings of this study?

Transcatheter aortic valve implantation was followed by significant changes in biomarkers, including an increase in fetuin-A (52.44 to 113.2 mg/ml) and decrease in H-FABP (4.835 to 2.534 ng/ml).

Key Result

Transcatheter aortic valve implantation was followed by significant changes in biomarkers, including an increase in fetuin-A (52.44 to 113.2 mg/ml) and decrease in H-FABP (4.835 to 2.534 ng/ml).

Study Design

Type

Cohort (n=79)

Structured PICO

Does TAVI alter the plasma levels of novel cardiovascular biomarkers in patients with severe aortic valve stenosis?

Population

79 patients with severe aortic valve stenosis undergoing TAVI, with blood samples collected before and up to 6 months post-procedure.

Exposure

Transcatheter aortic valve implantation (TAVI)

Comparator

Pre-TAVI baseline

Outcome

Change in plasma concentrations of GDF-15, H-FABP, fetuin-A, galectin 3, sST2 and suPAR measured by ELISA at 7 days, 1 month, 3 months and 6 months post TAVIsurrogate

TAVI induces significant dynamic changes in novel cardiovascular biomarkers, likely reflecting hemodynamic improvement, inflammatory stimuli, and mechanical strain.

Main Result

p-value: p=<0.001

Abstract

BACKGROUND: In this study we sought to examine whether transcatheter aortic valve implantation (TAVI) is followed by a change in the plasma levels of novel cardiovascular biomarkers. METHODS: We collected blood samples of 79 patients with severe aortic valve stenosis undergoing TAVI before and at 7 days, 1 month, 3 months and 6 months post TAVI and analyzed the plasma concentrations of GDF-15, H-FABP, fetuin-A, galectin 3, sST2 and suPAR by means of ELISA. RESULTS: There was a significant increase in the concentration of fetuin-A (median: 52.44 mg/ml to 113.2 mg/ml, p < 0.001) and a significant decrease of H-FABP after TAVI (median: 4.835 ng/ml to 2.534 ng/ml, p < 0.001). The concentrations of suPAR and sST2 showed an initial increase (suPAR median: 2755 pg/ml 3489 pg/ml, p < 0.001; sST2 median: 5832 pg/ml to 7137 pq/ml, p < 0.001) and subsequently decreased significantly. CONCLUSION: We hypothesize that the decrease of H-FABP and the increase of fetuin-A could be due to a hemodynamic improvement after valve replacement. The initial increase of suPAR could indicate an inflammatory stimulus and the significant increase in sST2 could be due to the mechanical strain caused by implantation of the valve.

Mark Helpful

Bookmark

Relay

Mark Helpful

Bookmark

Relay

Cite This Study

Mirna et al. (Wed,) conducted a cohort in Severe aortic valve stenosis (n=79). Transcatheter aortic valve implantation (TAVI) vs. Baseline (pre-TAVI) was evaluated on Change in plasma levels of novel cardiovascular biomarkers (GDF-15, H-FABP, fetuin-A, galectin 3, sST2, and suPAR) (p=<0.001). Transcatheter aortic valve implantation was followed by significant changes in biomarkers, including an increase in fetuin-A (52.44 to 113.2 mg/ml) and decrease in H-FABP (4.835 to 2.534 ng/ml).

synapsesocial.com/papers/6a220de82e065aea604932a6 https://doi.org/https://doi.org/10.1080/1354750x.2018.1499127

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: